Mayhew G, Perou C, Hayes N, Lai-Goldman M, and Faruki H.

Durham, NC, October 26, 2017— GeneCentric Therapeutics announced today that it will present data on the potential of non-small cell lung cancer (NSCLC) biologic subtypes based on its Cancer Subtyping Platform (CSP®) to provide novel biomarkers for response to PARP inhibitors. The data will be presented at a poster session during the 2017 American Association for Cancer Research – National Cancer Institute – European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Therapeutics being held October 27-30, 2017 at the Philadelphia Convention Center, Philadelphia, PA.

GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointments of Walter M. Capone as Chief Business Officer and Ellen Lubman to the company’s Board of Directors.

Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo (nivolumab)…

GeneCentric to Present Data at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long

On January 26, 2016 at 2:00 pm, GeneCentric’s Hawazin Faruki will speak at the Personalized Medicine World Conference (PMWC) 2016 Silicon Valley on “Genomic Tumor Profiling – Advancing Beyond Gene Mutations.” PMWC…

GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics, today announced that it will present new data on its lung cancer subtyping product, LSP™ 120, at the 16th World Conference on Lung Cancer being held September 6-9, 2015 at the Colorado Convention Center in Denver, CO.

On May 5, 2015, GeneCentric will present at the Southeast Investor & Venture Philanthropy Oncology Summit 2015. The Summit features more than 30 of the Southeast’s top private oncology companies. Attendees come…

GeneCentric is one of only 13 companies selected to participate at this year’s CED Life Science Conference Showcase. Dr. Myla Lai-Goldman, CEO of GeneCentric, will be presenting an overview of the company’s…